Source-grounded facts extracted from Elicio Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Elicio Therapeutics, Inc. terminated Capital on DemandTM Sales Agreement with JonesTrading Institutional Services LLC (effective 2026-03-16).
“On March 16, 2026, the Company delivered written notice to Jones to terminate the Jones Sales Agreement and the offering of shares contemplated thereby, effective upon delivery, pursuant to Section 12(b) of the Jones Sales Agreement.”
Elicio Therapeutics, Inc. entered into Sales Agreement with B. Riley Securities, Inc., JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. valued at $100.0 million (effective 2026-03-16).
“On March 16, 2026, Elicio Therapeutics, Inc. (the “ Company ”) entered into an At Market Issuance Sales Agreement (the “ Sales Agreement ”) with B. Riley Securities, Inc., JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. (the “ Agents ”) with respect to an at-the-market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share (the “ Common Stock ”), having an aggregate offering price of up to $100.0 million”
Elicio Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $39.5 million, EPS $2.58.
“Net loss for 2025 was $39.5 million, compared to $51.9 million for 2024. Net loss for 2025 includes $1.9 million of non-cash other expense resulting from the change in fair value of the warrant liability. Net loss per share for 2025 was $2.58, compared to $4.25 for 2024.”
Elicio Therapeutics, Inc. incurred senior notes of $10.0 million with GKCC, LLC at Prime Rate plus 5.00%, maximum 12.5% per annum maturing June 3, 2028.
“On June 3, 2025, Elicio Therapeutics, Inc. (the “Company”) entered into a note purchase agreement (the “Note Purchase Agreement”) pursuant to which the Company issued a Senior Secured Promissory Note due June 3, 2028 (the “Promissory Note”) in the principal amount of $10.0 million (the “Note Financing”).”
Preetam Shah was appointed as Chief Strategy and Financial Officer at Elicio Therapeutics, Inc..
“On March 21, 2025, Elicio Therapeutics, Inc. (the “Company”) appointed Preetam Shah, Ph.D., M.B.A., as the Company’s Chief Strategy and Financial Officer effective as of March 24, 2025 (the “Effective Date”).”
Robert Connelly was appointed as Principal Accounting Officer and Principal Financial Officer at Elicio Therapeutics, Inc..
“On October 15, 2024 , Elicio Therapeutics, Inc. (the “Company”) appointed Robert Connelly as the Company’s Principal Accounting Officer and Principal Financial Officer effective October 15, 2024.”
Brian Piekos resigned as Chief Financial Officer at Elicio Therapeutics, Inc..
“On August 27, 2024, Brian Piekos, the Chief Financial Officer and Treasurer of Elicio Therapeutics, Inc. (the “Company”), informed the Company of his intent to resign from his positions, effective September 6, 2024, to pursue another opportunity.”
Elicio Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $11.8 million, EPS $1.15.
“Net loss for the first quarter of 2024 was $11.8 million, compared to $8.0 million for the first quarter of 2023. Net loss per share for the first quarter of 2024 was $1.15 compared to $24.77 for the first quarter of 2023.”
Elicio Therapeutics, Inc. reported the year ending December 31, 2023 results: net income Net loss for 2023 was $35.2 million, EPS Net loss per share for 2023 was $6.96.
“Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2023 and provided corporate updates.”
Elicio Therapeutics, Inc. entered into Subscription Agreement with GKCC, LLC valued at approximately $6.0 million (effective 2024-03-18).
“On March 18, 2024, Elicio Therapeutics, Inc. (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with GKCC, LLC (the “Purchaser”), an entity controlled by a member of the board of directors of the Company, providing for the issuance and sale by the Company to the Purchaser of pre-funded warrants (the “Pre-Funded Warrants") to purchase up to 1,032,702 shares of common stock, par value $0.01 per share, of the Company (“Common Stock”), at a purchase price per Pre-Funded Warrant of $5.81 (the “Offering”).”
Elicio Therapeutics, Inc. entered into Subscription Agreement with GKCC, LLC valued at approximately $7.0 million (effective 2023-12-22).
“On December 22, 2023, Elicio Therapeutics, Inc. (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with GKCC, LLC (the “Purchaser”), an entity controlled by a director of the Company, providing for the issuance and sale by the Company to the Purchaser of an aggregate of 1,213,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a purchase price per Share of $5.81 (the “Offering”).”
Elicio Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.
“On November 9, 2023, Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”
Annette Matthies departed as Chief Business Officer at Elicio Therapeutics, Inc..
“On October 19, 2023 , Elicio Therapeutics, Inc. (the “Company”) and Annette Matthies, Ph.D., former Chief Business Officer of the Company, entered into a Separation and Release Agreement”
Annette Matthies departed as Chief Business Officer at Elicio Therapeutics, Inc..
“On October 5, 2023, Annette Matthies, Ph.D., Chief Business Officer of Elicio Therapeutics, Inc. (the “Company”) was terminated without cause, effective as of the same date (the “Separation Date”).”
Assaf Segal resigned as Director at Elicio Therapeutics, Inc..
“On August 28, 2023, Assaf Segal submitted his resignation from the Board of Directors (the “Board”) of Elicio Therapeutics, Inc. (the “Company”), which resignation was effective immediately.”
Elicio Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $7.6 million, EPS Net loss per share for the second quarter of 2023 was $2.61.
“Elicio Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2023.”
Elicio Therapeutics, Inc.: Name change amendment from Angion Biomedica Corp. to Elicio Therapeutics, Inc (effective 2023-06-01).
“Immediately prior to the consummation of the Merger, on June 1, 2023, Angion filed the Name Change Amendment changing its name from “Angion Biomedica Corp.” to “Elicio Therapeutics, Inc.””
Elicio Therapeutics, Inc. shareholders approved To elect the Angion Board nominees, Itzhak Goldberg, M.D., F.A.C.R. and Allen R. Nissenson, M.D., to the Angion Board in the class of directors to hold office until the 2026 Annual Meeting of Stockholders at the 2023-05-31 meeting.
“Proposal 4. To elect the Angion Board nominees, Itzhak Goldberg, M.D., F.A.C.R. and Allen R. Nissenson, M.D., to the Angion Board in the class of directors to hold office until the 2026 Annual Meeting of Stockholders: Name Votes For Votes Withheld Broker Non-Votes Itzhak Goldberg, M.D., F.A.C.R. 18,180,899 843,581 5,402,928 Allen R. Nissenson, M.D. 18,214,543 809,937 5,402,928”
Elicio Therapeutics, Inc. shareholders approved To approve an amendment to the Angion amended and restated certificate of incorporation of Angion to provide for the exculpation of officers at the 2023-05-31 meeting.
“Proposal 3. To approve an amendment to the Angion amended and restated certificate of incorporation of Angion to provide for the exculpation of officers: 17,192,853 For 248,833 Against 1,582,794 Abstain 5,402,928 Broker Non-Votes”
Elicio Therapeutics, Inc. shareholders approved To approve an amendment to the amended and restated certificate of incorporation of Angion to effect a reverse stock split of Angion common stock at a ratio within the range between 5-for-1 to 30-for-1 at the 2023-05-31 meeting.
“Proposal 2. To approve an amendment to the amended and restated certificate of incorporation of Angion to effect a reverse stock split of Angion common stock at a ratio within the range between 5-for-1 to 30-for-1: 22,792,786 For 449,015 Against 1,185,607 Abstain 0 Broker Non-Votes”
Elicio Therapeutics, Inc. shareholders approved To approve the issuance of shares of Angion capital stock pursuant to the Merger, which will represent more than 20% of the shares of Angion common stock outstanding immediately prior to the Merger and result in a change of control of Angion, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b) at the 2023-05-31 meeting.
“Proposal 1. To approve the issuance of shares of Angion capital stock pursuant to the Merger, which will represent more than 20% of the shares of Angion common stock outstanding immediately prior to the Merger and result in a change of control of Angion, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b): 17,841,302 For 1,109,168 Against 74,010 Abstain 5,402,928 Broker Non-Votes”
Elicio Therapeutics, Inc. underwent a change of control involving Elicio Therapeutics, Inc. (closed 2023-06-01).
“On June 1, 2023, the Delaware corporation formerly known as "Angion Biomedica Corp." completed its previously announced merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of January 17, 2023 (the "Merger Agreement"), by and among Angion Biomedica Corp. ("Angion"), Arkham Merger Sub, Inc., a wholly owned subsidiary of Angion ("Merger Sub"), and Elicio Therapeutics, Inc. ("Elicio"), pursuant to which Merger Sub merged with and into Elicio, with Elicio surviving the merger as a wholly owned subsidiary of Angion (the "Merger").”
Elicio Therapeutics, Inc. engaged Baker Tilly US, LLP as its auditor.
“(b) On June 1, 2023, the Audit Committee approved, on behalf of the Company, the engagement of Baker Tilly US, LLP (“Baker Tilly”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Elicio Therapeutics, Inc. dismissed Moss Adams LLP as its auditor.
“(a) On June 1, 2023, the Audit Committee (the “Audit Committee”) of the board of directors of the Company approved the dismissal of Moss Adams LLP (“Moss Adams”) as the Company’s independent registered public accounting firm, effective immediately.”
Assaf Segal was appointed as Class II Director at Elicio Therapeutics, Inc..
“Assaf Segal 51 Class II Director”
Robert R. Ruffolo, Jr. was appointed as Class II Director at Elicio Therapeutics, Inc..
“Robert R. Ruffolo, Jr., Ph.D., FCPP 73 Class II Director”
Yekaterina (Katie) Chudnovsky was appointed as Class I Director at Elicio Therapeutics, Inc..
“Yekaterina (Katie) Chudnovsky 38 Class I Director”
Carol Ashe was appointed as Class III Director at Elicio Therapeutics, Inc..
“Carol Ashe 65 Class III Director”
Julian Adams was appointed as Chair of the Board and Class III Director at Elicio Therapeutics, Inc..
“Julian Adams, Ph.D. 68 Chair of the Board and Class III Director”
Peter DeMuth was appointed as Chief Scientific Officer at Elicio Therapeutics, Inc..
“Peter DeMuth, Ph.D. 37 Chief Scientific Officer”
Annette Matthies was appointed as Chief Business Officer at Elicio Therapeutics, Inc..
“Annette Matthies, Ph.D. 46 Chief Business Officer”
Christopher Haqq was appointed as Executive Vice President, Head of Research and Development and Chief Medical Officer at Elicio Therapeutics, Inc..
“Christopher Haqq, M.D., Ph.D. 57 Executive Vice President, Head of Research and Development and Chief Medical Officer”
Brian Piekos was appointed as Chief Financial Officer at Elicio Therapeutics, Inc..
“Brian Piekos 48 Chief Financial Officer”
Robert Connelly was appointed as Chief Executive Officer, President and Class I Director at Elicio Therapeutics, Inc..
“Robert Connelly 63 Chief Executive Officer, President and Class I Director”
Ms. Rhodes changed role as Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary at Elicio Therapeutics, Inc..
“Ms. Rhodes, the former Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary, will step down from each such respective role, but will continue to be employed by the Company for a period of 30 days.”
Jay R. Venkatesan was terminated as other at Elicio Therapeutics, Inc..
“(ii) each of Gregory S. Curhan, Angion’s Chief Financial Officer and Jay R. Venkatesan, M.D., were terminated as employees of the Company effective as of the effective time of the Merger.”
Gregory S. Curhan was terminated as Chief Financial Officer at Elicio Therapeutics, Inc..
“(ii) each of Gregory S. Curhan, Angion’s Chief Financial Officer and Jay R. Venkatesan, M.D., were terminated as employees of the Company effective as of the effective time of the Merger.”
Gilbert S. Omenn resigned as director (resigned) at Elicio Therapeutics, Inc..
“each of Victor F. Ganzi, J.D., Itzhak D. Goldberg, M.D. and Gilbert S. Omenn, M.D., Ph.D., resigned from Angion’s board of directors and any respective committee membership of Angion’s board of directors, effective as of the effective time of Merger”
Itzhak D. Goldberg resigned as director (resigned) at Elicio Therapeutics, Inc..
“each of Victor F. Ganzi, J.D., Itzhak D. Goldberg, M.D. and Gilbert S. Omenn, M.D., Ph.D., resigned from Angion’s board of directors and any respective committee membership of Angion’s board of directors, effective as of the effective time of Merger”
Victor F. Ganzi resigned as director (resigned) at Elicio Therapeutics, Inc..
“each of Victor F. Ganzi, J.D., Itzhak D. Goldberg, M.D. and Gilbert S. Omenn, M.D., Ph.D., resigned from Angion’s board of directors and any respective committee membership of Angion’s board of directors, effective as of the effective time of Merger”
Elicio Therapeutics, Inc. entered into Agreement and Plan of Merger and Reorganization with Angion Biomedica Corp. (effective 2023-01-17).
“On January 17, 2023, Angion Biomedica Corp. , a Delaware corporation (“Angion”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Elicio Therapeutics, Inc., a Delaware corporation (“Elicio”)”
Elicio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“December 15, 2022, Angion Biomedica Corp. received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1). The notification received has no immediate effect on the listing of Angion ’s common stock on Nasdaq and Angion does not believe the notification will adversely impact its ongoing strategic realignment process, previous”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.